Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27% (CR 3% PR 21396). Median time to progression was 3.4 months (95% CI 1.1.-5.6 months) and median overall survival was 7.7 months (95% CI 5.7-9.8 months). Survival at I year was 28%, and at 2,ears, 10% MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.
- carcinoma of unknown primary site
- METASTATIC ADENOCARCINOMA